Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

Clinical Patterns and Subtypes

At a Glance

Autoimmune myocarditis has several patterns, including giant-cell, cancer-immunotherapy-associated, eosinophilic, and systemic autoimmune-associated forms. Identifying the pattern matters because some can worsen rapidly and require urgent, targeted immune treatment.

While “autoimmune myocarditis” is a broad term, doctors treat it as a category containing several overlapping clinical and histologic patterns. Identifying a specific pattern is valuable because it can dictate how aggressively your team must act and which medications will be most effective [1][2][3].

Giant-Cell Myocarditis Pattern

Giant-Cell Myocarditis (GCM) is the most severe and rapidly progressing pattern. It is characterized by the presence of “multinucleated giant cells” in the heart muscle [1][4].

  • Who it affects: Most commonly middle-aged adults [5].
  • The Risk: It can lead to rapid hemodynamic or rhythm deterioration within days or even hours [5][6].
  • Treatment: Because of its intensity, urgent combination immunosuppression is commonly used, and patients often require care at a specialist center [4][7].

Immune Checkpoint Inhibitor (ICI) Myocarditis

This pattern is a unique complication of modern cancer treatments known as Immune Checkpoint Inhibitors (such as PD-1 or CTLA-4 inhibitors). These drugs work by “releasing the brakes” on your immune system so it can fight cancer, but sometimes the immune system begins to attack the heart instead [8][9].

  • Timing: It typically occurs early in treatment, though it can occasionally happen much later [8][9].
  • The “Triple-M” Syndrome: Patients with ICI myocarditis may also experience myositis (muscle inflammation) and myasthenia gravis (severe muscle weakness), which can affect breathing [10][11].
  • The Risk: This form is highly “pro-arrhythmic,” meaning it frequently causes electrical issues in the heart even if the heart’s pumping strength remains normal [8][12].

Eosinophilic Myocarditis Pattern

In this pattern, the heart is infiltrated by eosinophils, a specific type of white blood cell usually involved in allergic reactions or fighting parasites [2].

  • Triggers: It can be triggered by drug hypersensitivity, parasitic infections, or systemic conditions like Eosinophilic Granulomatosis with Polyangiitis (EGPA) [13][14].
  • The Signs: While some patients have high levels of eosinophils in their blood (peripheral eosinophilia), a normal eosinophil count does not exclude the diagnosis, making a heart biopsy essential for diagnosis in some cases [15][16].
  • Treatment: Identifying and stopping a culprit drug or treating the underlying cause is part of management, alongside corticosteroids to clear the eosinophils from the heart tissue [2][17].

Systemic Autoimmune-Associated Myocarditis

Sometimes, myocarditis is just one part of a larger autoimmune flare-up involving the whole body. This is common in “connective tissue diseases” [3][18].

  • Common Associations: Conditions like Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, and Cardiac Sarcoidosis (a distinct inflammatory condition) can all involve the heart [19][3].
  • The Presentation: In some cases, myocarditis is the very first sign of a disease like Lupus, appearing before any joint pain or rashes [20].
  • Treatment: The focus is on treating the underlying systemic disease, though the cardiac inflammation may require dedicated therapies and does not always resolve automatically [20][21].
Pattern Primary Risk Common Trigger
Giant-Cell Rapid hemodynamic or rhythm deterioration Often unknown; autoimmune link [7]
ICI-Associated Sudden heart block/Arrhythmia Cancer immunotherapy [8]
Eosinophilic Possible thromboembolic complications in selected cases Medications, parasites, or systemic syndromes [15]
Systemic/Lupus Part of a whole-body flare Chronic autoimmune disease [3]

Understanding these overlapping categories allows your doctors to move past generalized care and provide the specific, targeted treatment your heart needs to heal [4][1].

Common questions in this guide

What are the main types of autoimmune myocarditis?
The main patterns include giant-cell myocarditis, immune checkpoint inhibitor-associated myocarditis, eosinophilic myocarditis, and myocarditis linked to systemic autoimmune disease. Each pattern has different triggers, risks, testing needs, and treatment considerations.
How serious is giant-cell myocarditis?
Giant-cell myocarditis is a severe form that can cause rapid worsening of blood flow or heart rhythm within days or even hours. It commonly requires urgent combination immune-suppressing treatment and care at a specialist center.
What is immune checkpoint inhibitor myocarditis?
Immune checkpoint inhibitor myocarditis is heart inflammation caused by cancer immunotherapy that activates the immune system. It often develops early in treatment and can cause serious rhythm problems even when the heart’s pumping strength is normal; muscle inflammation or severe muscle weakness may occur at the same time.
Can a normal eosinophil blood count rule out eosinophilic myocarditis?
No. Some people with eosinophilic myocarditis do not have an increased eosinophil count in their blood, so a normal result does not exclude the condition. In some cases, a heart biopsy is needed to identify eosinophils in the heart tissue.
How is the autoimmune myocarditis subtype identified?
Doctors may use the clinical course, imaging, blood tests, and sometimes a heart biopsy to determine the pattern. The findings can help the team judge how urgently to monitor you and which immune-suppressing treatment is most appropriate.
Can lupus or another autoimmune disease cause myocarditis?
Yes. Myocarditis can occur with systemic lupus erythematosus, rheumatoid arthritis, cardiac sarcoidosis, and other connective tissue diseases. It can sometimes be the first sign of a systemic illness, so treatment may need to address both the heart inflammation and the underlying disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my biopsy or imaging, which specific subtype of autoimmune myocarditis do I have?
  2. 2.How does my specific subtype change the urgency or the type of immunosuppression I will receive?
  3. 3.If I have ICI-associated myocarditis, should I also be screened for myositis (muscle inflammation) or myasthenia gravis?
  4. 4.Is my myocarditis likely to be 'fulminant' (rapidly progressing), and should I be monitored in an intensive care setting?
  5. 5.For my subtype, what is the risk of the inflammation returning once we begin tapering my medications?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Inflammatory Cardiomyopathic Syndromes.

    Trachtenberg BH, Hare JM

    Circulation research 2017; (121(7)):803-818 doi:10.1161/CIRCRESAHA.117.310221.

    PMID: 28912184
  2. 2

    [Ten questions about eosinophilic myocarditis].

    Pagura L, Imazio M, Merlo M, Sinagra G

    Giornale italiano di cardiologia (2006) 2022; (23(4)):259-267 doi:10.1714/3766.37535.

    PMID: 35343477
  3. 3

    Myocarditis in connective tissue diseases: an often-overlooked clinical manifestation.

    Azzam M, Awad A, Abugharbyeh A, Kahaleh B

    Rheumatology international 2023; (43(11)):1983-1992 doi:10.1007/s00296-023-05428-w.

    PMID: 37587233
  4. 4

    Giant Cell Myocarditis: An Updated Review of Pathogenesis, Clinical Presentation, and Modern Management Approaches.

    Elattar S, Hassid Y, Cheikhali R, et al.

    Cardiology in review 2025; doi:10.1097/CRD.0000000000001123.

    PMID: 41198092
  5. 5

    Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis.

    Chiu MH, Trpkov C, Rezazedeh S, Chew DS

    Case reports in cardiology 2019; (2019()):7276516 doi:10.1155/2019/7276516.

    PMID: 31321103
  6. 6

    Incidence, Risk Factors, and Outcome of Life-Threatening Ventricular Arrhythmias in Giant Cell Myocarditis.

    Ekström K, Lehtonen J, Kandolin R, et al.

    Circulation. Arrhythmia and electrophysiology 2016; (9(12)).

    PMID: 27913400
  7. 7

    Fulminant myocarditis: outcome predictors in an international cohort study.

    Majunke N, Haertel F, Binzenhöfer L, et al.

    European heart journal 2025; doi:10.1093/eurheartj/ehaf671.

    PMID: 40928499
  8. 8

    Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

    Mahmood SS, Fradley MG, Cohen JV, et al.

    Journal of the American College of Cardiology 2018; (71(16)):1755-1764 doi:10.1016/j.jacc.2018.02.037.

    PMID: 29567210
  9. 9

    Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review.

    Pradhan R, Nautiyal A, Singh S

    International journal of cardiology 2019; (296()):113-121 doi:10.1016/j.ijcard.2019.07.025.

    PMID: 31327516
  10. 10

    PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients.

    He Y, Chen W, Cai J, et al.

    Journal of thoracic disease 2023; (15(9)):4606-4619 doi:10.21037/jtd-23-596.

    PMID: 37868865
  11. 11

    Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment.

    Wang C, Lin J, Wang Y, et al.

    Frontiers in pharmacology 2021; (12()):770631 doi:10.3389/fphar.2021.770631.

    PMID: 34938185
  12. 12

    Characterization of Cardiovascular Events and Prognosis in Immune Checkpoint Inhibitor-Related Myocarditis.

    Pereyra Pietri M, Farina JM, Scalia IG, et al.

    Mayo Clinic proceedings 2025; (100(12)):2140-2151 doi:10.1016/j.mayocp.2024.12.017.

    PMID: 40202477
  13. 13

    Cardiac involvement in DRESS syndrome.

    Thongsri T, Chularojanamontri L, Pichler WJ

    Asian Pacific journal of allergy and immunology 2017; (35(1)):3-10 doi:10.12932/AP0847.

    PMID: 27996289
  14. 14

    [Cardiac involvement in Churg-Strauss syndrome].

    Brucato A, Maestroni S, Masciocco G, et al.

    Giornale italiano di cardiologia (2006) 2015; (16(9)):493-500 doi:10.1714/1988.21524.

    PMID: 26418389
  15. 15

    Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes.

    Brambatti M, Matassini MV, Adler ED, et al.

    Journal of the American College of Cardiology 2017; (70(19)):2363-2375 doi:10.1016/j.jacc.2017.09.023.

    PMID: 29096807
  16. 16

    Fulminant Eosinophilic Myocarditis Without Peripheral Eosinophilia.

    Lee JY, Lee SH, Kim WH

    Texas Heart Institute journal 2023; (50(2)) doi:10.14503/THIJ-21-7818.

    PMID: 37044058
  17. 17

    Eosinophilic Myocarditis.

    Cheung CC, Constantine M, Ahmadi A, et al.

    The American journal of the medical sciences 2017; (354(5)):486-492 doi:10.1016/j.amjms.2017.04.002.

    PMID: 29173361
  18. 18

    Myocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis. A systematic review.

    Cheng CY, Baritussio A, Giordani AS, et al.

    Autoimmunity reviews 2022; (21(4)):103037 doi:10.1016/j.autrev.2022.103037.

    PMID: 34995763
  19. 19

    Myocardial Involvement in Systemic Autoimmune Rheumatic Diseases.

    Zagouras AA, Tang WHW

    Rheumatic diseases clinics of North America 2023; (49(1)):45-66 doi:10.1016/j.rdc.2022.08.002.

    PMID: 36424026
  20. 20

    Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients.

    Thomas G, Cohen Aubart F, Chiche L, et al.

    The Journal of rheumatology 2017; (44(1)):24-32 doi:10.3899/jrheum.160493.

    PMID: 28042125
  21. 21

    Fatal Myopericarditis in a Patient With Lupus Erythematosus Supported by Extracorporeal Membrane Oxygenation: A Case Report.

    Lee SY, Park JH, Shin DH, et al.

    Journal of rheumatic diseases 2021; (28(3)):165-170 doi:10.4078/jrd.2021.28.3.165.

    PMID: 37475997

This page explains autoimmune myocarditis patterns for informational purposes only and does not constitute medical advice. Because some forms can worsen quickly, discuss symptoms and treatment decisions promptly with your cardiology team.

Get notified when new evidence is published on Autoimmune myocarditis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.